Topic Listing for AMAG Pharmaceuticals

Ability Grow Revenues Sales Feraheme Limited Not Obtain Ability Net Operating Loss Carryforwards Tax Credit Offset
Absence Material Changes Accompanying Notes Integral Part Condensed Consolidated Financial Statements
Accounting Controls Accounts Receivable
Accrued Expenses Additional Indemnification Rights
Advancement Expenses Adverse Event Reporting
Advertising Costs Agreements Sell Purchase
Amag Pharmaceuticals Inc Amag Pharmaceuticals Inc Contacts
Amended Restated Employment Agreement Annual Performance Bonus
Applicable Law Auction Rate Securities Ubs Settlement Rights
Available Information Backlog
Basis Presentation Bayer
Been Expect Continue Number Federal State Proposals Reform Benefits Life Insurance
Brokers Fees Business Highlights
Business Segments Cannot Produce Sufficient Quantities Feraheme Manufacturing Facility Need
Capitalization Cash Equivalents
Cash Flows Financing Activities Cash Flows Investing Activities
Cash Flows Operating Activities Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act
Certifications Changes Critical Accounting Policies
Changes Internal Control Over Financial Reporting Chargebacks
Chronic Kidney Disease Anemia Iron Deficiency Classification Product Sales Allowance Accruals
Classification Product Sales Allowances Accruals Clinical Development
Clinical Studies Code Ethics
Collaborative Agreements Contracts Commercial Launch Feraheme
Commitments Contingencies Common Stock Transactions
Competition Compliance
Compliance Environmental Laws Compliance Form Disclosure
Comprehensive Income Loss Comprehensive Loss
Concentration Credit Risk Concentrations Significant Customer Information
Conditions Underwriters Obligations Conflict
Consent Independent Registered Public Accounting Firm Consents Required
Contractual Obligations Controls Procedures
Core Technology Corrupt Practices
Cost Product Sales Counterparts
Covenants Covenants Underwriters
Covidien Current Credit Financial Market Conditions Exacerbate Certain Risks
Current Long-term Liabilities Dated
Deferred Revenue Launch Incentive Program Deferred Revenue-launch Incentive Program
Deferred Revenues Delaware
Departures Directors Certain Officers Election Appointment Compensatory Description Capital Stock
Disclosure Controls Discounts
Distributor Wholesaler Group Purchasing Organization Fees Dividends
Due Authorization Enforceability Due Incorporation
Effectiveness Defaulting Underwriters Employee Savings Plan
Employee Stock Purchase Plan Employees
Enter Collaborations In-licensing Arrangements Acquisition Agreements Disrupt Business Entered Collaboration Exclusive License Agreement 3sbio Respect
Entire Agreement Entry Material Definitive Agreement
Equity-based Compensation Equity-based Compensation Expense
Erisa Estimates Assumptions
Estimates Make Assumptions Rely Preparing Consolidated Financial Statements Exceptions
Exchange Act Requirements Exposed Number Different Potential Liability Claims Not Able
Fda Post-approval Requirements Fda Regulation Manufacturing Facilities
Fda Regulation Product Marketing Promotion Feraheme
Feraheme Indications Other Ckd Feraheme Iron Replacement Therapeutic
Feraheme Not Widely Adopted Physicians Patients Healthcare Payors Feridex
Feridex Liver Contrast Agent Had Been Marketed Sold Ferumoxytol Diagnostic Agent Vascular Enhancement Mri
Financial Statements Financial Statements Exhibits
Finra Review Foreign Operations
Foreign Regulatory Process Form 10-k
Form 10-q Forward Looking Statement
Forward Looking Statements Fraud Abuse Regulation
Free Writing Prospectuses Gastromark
Good Title Property Governmental Other Rebates
Gross-up Payments Guerbet
Headings History Net Losses Not Able Generate Sufficient Revenues
Identify Material Weakness Internal Controls Over Financial Reporting Impact Recently Issued Accounting Standards
Impact Recently Issued Proposed Accounting Pronouncements Important Safety Information Feraheme
Inability Obtain Raw Materials Reliance Sole Source Suppliers Income Tax Benefit
Income Taxes Indemnification Agreements
Indemnification Obligations Indemnity Contribution
Independent Accountants Index
Initial Indemnity Insurance
Intellectual Property Rights International Expansion
Inventories Investment Cash Subject Risks Cause Losses Adversely Affect
Investments Label Expansion
Labor Disputes Legal Proceedings
Lexington Lexington 2009
License Fee Revenues Licensing Marketing Supply Arrangements
Limited Experience Independently Commercializing Pharmaceutical Product Failure Part Limited Experience Independently Distributing Pharmaceutical Product Feraheme Commercialization
List Exhibits Managements Annual Report Internal Control Over Financial Reporting
Managements Evaluation Disclosure Controls Procedures Manufacturing
Market Distribute Products Manner Violates Federal State Healthcare Market Information
Material Adverse Change Money Laundering
More- Multiple Element Arrangements
Mutual Acknowledgement Regarding Public Policy Nasdaq Exchange Act Registration
Need Additional Capital Achieve Business Objectives Net Loss
Net Loss Per Share Net Product Sales
Nference Call Webcast Access Not Effectively Manage Growth Ability Commercialize Feraheme Pursue
Not Investment Notices
Number 0-14732 Off-balance Sheet Arrangements
Office Foreign Assets Control Operating Facility Lease Obligations
Operating Results Likely Fluctuate Not Rely Single Predict Organization Business
Other Events Other Income Expense
Other Long-term Liabilities Other Regulatory Requirements
Overview Patents Trade Secrets
Payment Delivery Payments Benefits Due Change Control
Permits Physicians Patients Healthcare Payors Major Operators Dialysis Clinics
Plan Preferred Stock
Preliminary Prospectuses Price Stabilization
Principles Consolidation Product Returns
Product Sale Revenues Products
Property Plant Equipment Property Plant Equipment Consisted Following 2009 2008 Respectively
Public Offering Purchase Commitments
Pursuant Requirements Securities Exchange Act 1934 Registrant Duly Quantitative Qualitative Disclosures Market Risk
Rated Debt Raw Materials
Realized Gains Losses Recently Issued Proposed Accounting Pronouncements
Reclassifications Registrants Telephone Number Including Area Code Securities Registered
Registration Rights Registration Statement Effective Eligibility
Regulation Reimbursement
Rely Parties Conduct Clinical Trials They Fail Fulfill Representations Warranties
Repurchases Equity Securities Research Development
Research Development Expenses Results Operations Financial Condition
Results Operations Financial Conditions Revenues
Royalty Revenues Salary
Sales Marketing Distribution Sarbanes-oxley Act
Sarbanes-oxley Act 2002 Sbio
Schedule Securities Analysts Downgrade Stock Cease Coverage Operating Results
Selling General Administrative Expenses Severance Arrangements
Severance Due After Termination Employment Shares
Shipping Handling Costs Signatures
Significant Safety Drug Interaction Problems Arise Respect Feraheme Solely Dependent Success Feraheme
Statistical Market-related Data Statutes Contracts
Stock Options Granted Consultants Stock Price Been Continue Volatile Investment Decline Value
Stockholders Stockholders Equity
Subject Class Action Litigation Due Stock Price Volatility Subject Environmental Laws Potential Exposure Liabilities
Subject Ongoing Regulatory Review Feraheme Fail Comply Such Submission Fda Review Nda
Subrogation Duplication Payments Subsequent Events
Subsidiaries Subsidiaries Amag Pharmaceuticals Inc
Success Depends Ability Attract Retain Key Employees Success Depends Ability Maintain Proprietary Nature Technology
Taxes Term Amended Restated Agreements
Termination Underwriting Agreement
Undisclosed Relationships Unregistered Sales Equity Securities Proceeds
Valuation Qualifying Accounts Value Received Hereby Sell Assign Transfer Unto
Violation Webcast Information
Wholesaler Distributor Buying Patterns Other Factors Cause Quarterly 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki